<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657006</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9581-IG-CTIL</org_study_id>
    <nct_id>NCT01657006</nct_id>
  </id_info>
  <brief_title>HeartTrends Heart Rate Variability (HRV) Algorithm for the Diagnosis of Myocardial Ischemia</brief_title>
  <official_title>HeartTrends HRV Algorithm for the Diagnosis of Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to prospectively enroll consecutive patients, without known ischemic&#xD;
      heart disease, referred by their physician for routine exercise MPI at a tertiary care&#xD;
      center.&#xD;
&#xD;
      Prior to the MPI (nuclear stress test), eligible and consenting patients will undergo a&#xD;
      one-hour period of Holter ECG digital recording. Application of ECG electrodes will be&#xD;
      performed by medical technicians following standard recommendations, utilizing approved&#xD;
      Holter device &amp; stickers. The Holter ECG data will be used for the offline heart rate&#xD;
      variability (HRV) analysis by the HeartTrends device.&#xD;
&#xD;
      Immediately following data acquisition, all patients will undergo an exercise MPI according&#xD;
      to accepted clinical practice guidelines.&#xD;
&#xD;
      Following the MPI, there will be no interference with patient management, which will be&#xD;
      conducted by the patients' treating physicians according to current guidelines, unaware of&#xD;
      HRV results.&#xD;
&#xD;
      Analysis of recorded ECG data for HRV will be performed blinded to the EST and MPI results,&#xD;
      by HeartTrends device.&#xD;
&#xD;
      The results of the HRV tests will not be available to treating physicians and will not be&#xD;
      used to guide patient management. Patients will be followed for 6 months for the occurrence&#xD;
      of coronary interventions and MACE, defined as: death, myocardial infarction, unstable&#xD;
      angina, or any coronary revascularization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the HeartTrends device for the detection of myocardial ischemia</measure>
    <time_frame>6 month</time_frame>
    <description>sensitivity of the HeartTrends device in comparison to conventional exercise stress testing for the purpose of diagnosing significant myocardial ischemia based on exercise myocardial perfusion imaging examination (considered as the &quot;gold standard&quot;)</description>
  </primary_outcome>
  <enrollment type="Actual">450</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will prospectively enroll consecutive patients, without known ischemic heart&#xD;
        disease, referred by their physician for an exercise MPI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 21&#xD;
&#xD;
          -  Referral for exercise MPI by treating physicians&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Established ischemic heart disease&#xD;
&#xD;
          -  Atrial fibrillation or flutter&#xD;
&#xD;
          -  Acute Coronary Syndrome&#xD;
&#xD;
          -  Cardiac Pacemaker&#xD;
&#xD;
          -  Clinical diagnosis of heart failure&#xD;
&#xD;
          -  Moderate or severe COPD&#xD;
&#xD;
          -  Active myocarditis, constrictive pericarditis, any cardiomyopathy, cardiac or systemic&#xD;
             amyloidosis&#xD;
&#xD;
          -  Known drug or alcohol dependence or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results or in the opinion of the investigator&#xD;
             are not suitable to participate;&#xD;
&#xD;
          -  Any illness that might reduce life expectancy to less than 1 year from screening&#xD;
&#xD;
          -  Left bundle branch block (LBBB), significant intra-ventricular conduction delay (IVCD)&#xD;
             or significant (&gt;1mm) ST deviations on baseline ECG&#xD;
&#xD;
          -  Inability to perform an exercise stress test (i.e. orthopedical or neurological&#xD;
             limitations)&#xD;
&#xD;
          -  Any significant established myocardial or valvular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilan Goldenberg, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart rate variability</keyword>
  <keyword>ischemic heart disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

